Becton Dickinson announced the enrollment of the first patient in the investigational device exemption, or IDE, study, AGILITY, which will assess the safety and effectiveness of the BD Vascular Covered Stent for the treatment of Peripheral Arterial Disease, or PAD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BDX:
- Becton Dickinson Executive Retirement and Succession Plan
- Becton Dickinson enters pact with Camtech to advance cervical cancer screening
- GD, BDX, SYY: 3 Best Dividend Aristocrats with Plenty of Upside Potential
- Becton Dickinson Issues Euro and USD Debt Notes
- Becton Dickinson Launches Billion-Dollar Note Offerings
